Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Veno-occlusive disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Veno-occlusive disease. Displaying page 1 of 1.
    EudraCT Number: 2016-002004-10 Sponsor Protocol Number: 15-007 Start Date*: 2016-10-13
    Sponsor Name:Jazz Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Un...
    Medical condition: Prevention of Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell Transplant
    Disease: Version SOC Term Classification Code Term Level
    19.0 10019805 - Hepatobiliary disorders 10047207 Veno-occlusive liver damage LLT
    19.0 10019805 - Hepatobiliary disorders 10047217 Venoocclusive syndrome of the liver LLT
    19.0 10019805 - Hepatobiliary disorders 10047216 Venoocclusive liver disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) DE (Prematurely Ended) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000592-33 Sponsor Protocol Number: N/A Start Date*: 2006-03-02
    Sponsor Name:Gentium S.p.A [...]
    1. Gentium S.p.A
    2. EBMT Trial Office
    Full Title: Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation
    Medical condition: Hepatic veno-occlusive disease following hematopoietic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047217 Venoocclusive syndrome of the liver LLT
    9.1 10047207 Veno-occlusive liver damage LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) GB (Completed) AT (Completed) IT (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004316-18 Sponsor Protocol Number: 2006-05 Start Date*: 2017-11-21
    Sponsor Name:Jazz Pharmaceuticals
    Full Title: Defibrotide for Patients with Hepatic Veno-occlusive Disease (VOD): A Treatment IND Study
    Medical condition: Hepatic Veno-Occlusive Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10047207 Veno-occlusive liver damage LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-001557-27 Sponsor Protocol Number: B1931030 Start Date*: 2019-02-17
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CE...
    Medical condition: ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10024329 Leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BE (Completed) HU (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-002996-34 Sponsor Protocol Number: PK 2005 xx Start Date*: 2006-04-27
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: Pharmacokinetics of actinomycin D in children with cancer
    Medical condition: Any children's cancer where this drug is administered as part of the treatment regimen
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-003739-30 Sponsor Protocol Number: AMLSG 05-04 Start Date*: 2005-11-02
    Sponsor Name:Universitätsklinikum Ulm / University Clinical Center Ulm
    Full Title: Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM]
    Medical condition: primary refractory patients with acute myeloid leukemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003392-17 Sponsor Protocol Number: BUSEQ-IPC2020-006 Start Date*: 2021-02-17
    Sponsor Name:Institut Paoli-Calmettes
    Full Title: SEQUENTIAL AND PERSONALIZED BUSULFAN ADMINISTRATION BY PHARMACOKINETICS IN ALLOGENIC GRAFT CONDITIONING FOR PATIENTS WITH MALIGNANT HEMOPATHIA NOT ELIGIBLE FOR STANDARD MYELOABLATIVE PACKAGIN
    Medical condition: Acute Leukemia Mielodysplasic Syndrome Myeloproliferative Neoplasm
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004800-23 Sponsor Protocol Number: RG-17-241 Start Date*: 2018-06-12
    Sponsor Name:University of Birmingham
    Full Title: A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in co...
    Medical condition: Acute Lymphoblastic Leukaemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-002584-41 Sponsor Protocol Number: CEPOETA-2015-01 Start Date*: 2016-10-24
    Sponsor Name:Masarykova univerzita
    Full Title: RECURENT NEUROBLASTOMA AND EWING´S SARCOMA: TREOSULPHAN BASED HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS PBSC SUPPORT
    Medical condition: Ewing's sarcoma, neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001513-35 Sponsor Protocol Number: Start Date*: 2016-08-23
    Sponsor Name:NHS Blood and Transplant. [...]
    1. NHS Blood and Transplant.
    2. NHS Blood and Transplant
    Full Title: TREATT: TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia A double blind, randomised controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with haematologic...
    Medical condition: Bleeding secondary to thrombocytopaenia associated to haematological malignancies.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10005103 Bleeding LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-005491-41 Sponsor Protocol Number: B1931022 Start Date*: 2012-06-13
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia...
    Medical condition: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) ES (Completed) GB (Completed) DE (Completed) FI (Completed) IT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001684-89 Sponsor Protocol Number: RG_20-030 Start Date*: 2020-05-05
    Sponsor Name:University of Birmingham
    Full Title: CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004855 10047468 Viral lower respiratory tract infections HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001656-19 Sponsor Protocol Number: RP-L301-0119 Start Date*: 2019-09-19
    Sponsor Name:Rocket Pharmaceuticals, Inc.
    Full Title: Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the Codon O...
    Medical condition: Pyruvate kinase deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002680-26 Sponsor Protocol Number: RP-L201-0218 Start Date*: 2018-11-27
    Sponsor Name:Rocket Pharmaceuticals, Inc.
    Full Title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lenti...
    Medical condition: Leukocyte Adhesion Deficiency-I (LAD-I)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018137 Genetic anomalies of leukocytes LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003282-36 Sponsor Protocol Number: 123123 Start Date*: Information not available in EudraCT
    Sponsor Name:Västra Götalands Regionen
    Full Title: A Randomized, Multi-Center Phase III Trial comparing two conditioning regimens (CloFluBu and BuCyMel) in children with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation.
    Medical condition: Acute myeloid leukemia (AML) in children
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003530-85 Sponsor Protocol Number: GITMO-PHYLOS Start Date*: 2019-10-02
    Sponsor Name:GITMO GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA
    Full Title: Post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Cell Transplantation for Myeloid Malignancies
    Medical condition: Acute myeloid leukemia or myelodysplastic syndrome undergoing 1 antigen/allele mismatched (7/8 HLA matched) unrelated HCT
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10068372 Prophylaxis against stem cell transplant rejection LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004324-14 Sponsor Protocol Number: WU-CART-007-1001 Start Date*: 2023-06-26
    Sponsor Name:Wugen, Inc.
    Full Title: A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic L...
    Medical condition: Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042987 T-cell type acute leukaemia PT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005066-30 Sponsor Protocol Number: RG_14-088 Start Date*: 2018-03-20
    Sponsor Name:The University of Birmingham
    Full Title: MyeChild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with ...
    Medical condition: Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplastic syndrome(MDS) and isolated myeloid sarcoma (either de novo or secondary) are eligible for the trial.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:39:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA